Globis Acquisition, a blank check company formed by Globis Capital Advisors and Chardan targeting economic globalization, raised $100 million by offering 10 million units at $10. Each unit will consist of one share of common stock and one whole warrant, exercisable at $11.50.
Th
EdtechX Holdings Acquisition II, the second blank check company formed by IBIS Capital to acquire an education technology business, raised $100 million by offering 10 million units at $10. Each unit consists of one share of common stock and one-half of a warrant, exercisable at $
Roth CH Acquisition II, the second blank check company formed by executives at Roth Capital and Craig-Hallum, raised $100 million by offering 10 million units at $10. Each unit consists of one share of common stock and one-half of a warrant, exercisable at $11.50. The company ori
Gores Holdings VI, the sixth blank check company formed by The Gores Group, raised $300 million by offering 30 million units at $10. Each unit consists of one share of common stock and one-fifth of a warrant, exercisable at $11.50.
For access to advanced SPAC tracking, filtering
Motive Capital, a blank check company formed by Motive Partners targeting the fintech sector, raised $360 million by offering 36 million units at $10. The company offered 6 million more units than anticipated. Each unit consists of one share of common stock and one-third of
Delwinds Insurance Acquisition, a blank check company formed by The Gray Insurance Company targeting the insurance industry, raised $175 million by offering 17.5 million units at $10. Each unit consists of one share of common stock and one-half of a warrant, exercisable at $11.50
Senior Connect Acquisition I, a blank check company formed by the founder of UnitedHealth targeting the senior market, raised $360 million by offering 36 million units at $10. The company offered 6 million more units than anticipated. Each unit consists of one share of common sto
Vivos Therapeutics, which is commercializing non-invasive medical devices for sleep disordered breathing, raised $21 million by offering 3.5 million shares at $6, within the range of $5 to $7. The company offered 0.2 million more shares than anticipated. At pricing, the company r
AbCellera Biologics, which provides an AI powered drug discovery platform for antibody therapies, raised $483 million by offering 24.2 million shares at $20, above the upwardly revised range of $17 to $18. The company offered 1.2 million more shares than anticipated. It originall
4D Molecular Therapeutics, a Phase 1/2 gene therapy biotech developing novel AAVs for ophthalmic diseases, raised $193 million by offering 8.4 million shares at $23, the high end of the upwardly revised range of $22 to $23. The company offered 1.4 million more shares than anticip
CBRE Acquisition Holdings, a blank check company formed by real estate giant CBRE targeting growth companies, raised $350 million by offering 35 million units at $10. The offered units consist of one share of common stock and one quarter warrant, exercisable at $11.00. The c
Certara, which provides biosimulation software and services used for drug development, raised $668 million by offering 29.1 million shares (50% primary) at $23, above the range of $19 to $22.
The company originally filed to offer 24.4 million shares (58% primary), but selling s
Nanobiotix, a late-stage French developer of nanoparticle drugs that improve cancer radiotherapy, raised $99 million by offering 7.3 million ADS equivalents at $13.50, the low end of the range of $13.50 to $14.50. The company offered 0.8 million more ADS equivalents than anticipa
The IPO market remained super solid this year. Though Renaissance IPO ETF IPO lost 3.1% on Dec 9 on broader market concerns, the prospect looks pretty upbeat. There have been 205 IPOs priced this year, up 34.9% from last year, per renaissancecapital. Total proceeds raised are $74
AbCellera Biologics, which provides an AI powered drug discovery platform for antibody therapies, raised the proposed deal size for its upcoming IPO on Thursday.
The Vancouver, Canada-based company now plans to raise $403 million by offering 23 million shares at a price range of
4D Molecular Therapeutics, a Phase 1/2 gene therapy biotech developing novel AAVs for ophthalmic diseases, raised the proposed deal size for its upcoming IPO on Thursday.
The Emeryville, CA-based company now plans to raise $158 million by offering 7 million shares at a price ran
Airbnb, which provides a platform for booking short-term stays from a global network of locals, raised $3.5 billion by offering 51.3 million shares (97% primary) at $68, well above the upwardly revised range of $56 to $60.
The company initially planned to offer its shares
Airbnb, which provides a platform for booking short-term stays from a global network of locals, raised $3.5 billion by offering 51.3 million shares (97% primary) at $68, well above the upwardly revised range of $56 to $60. The company originally planned to offer its shares at a r
Renaissance Capital
Checked
31 minutes 22 seconds ago
This feed is responsible for generating the rss feed related to the topic IPOs